title: Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
abstract: BACKGROUND
  Thirty previously untreated patients with metastatic colorectal carcinoma were randomized as part of two multicenter Phase III trials. Twenty-two patients were randomized to receive either 5-fluorouracil (5-FU)/interferon alfa-2A (IFN-alpha) or 5-FU/leucovorin (11 patients in each arm). Eight patients were randomized to receive 5-FU/IFN-alpha or 5-FU alone (4 patients in each arm).
  
  
  METHODS
  Twenty-three patients (13 patients treated with 5-FU/IFN-alpha and 10 patients treated with 5-FU/leucovorin or 5-FU alone) were evaluated regularly for response by computed tomography (CT) scans of the abdomen when treatment began and then every 6-8 weeks.
  
  
  RESULTS
  Incidentally, four patients developed hepatic steatosis during treatment with IFN-alpha and 5-FU. The diagnosis was based on a decreased CT value of the liver parenchyma by repeated CT scans of the abdomen during treatment, and this diagnosis was verified histologically by liver biopsy. There was no relationship to cumulative IFN-alpha or 5-FU dose. Based on posttreatment CT scans, the liver parenchyma changes were reversible after therapy was stopped, and there were no significant clinical sequelae. No patients treated with 5-FU/leucovorin or 5-FU alone experienced a decreased CT value of the liver parenchyma.
  
  
  CONCLUSIONS
  Hepatic steatosis was been observed in approximately 30% of patients treated with IFN-alpha and 5-FU. The hepatic changes were fully reversible after the treatment was stopped. Recognition of this condition is important to prevent a patient from being labeled as having progressive hepatic metastases.
authors.affiliation: Department of Oncology, Odense Univesity Hospital, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Sørensen
authors.forename: A L
authors.initials: AL
authors.lastname: Edal
authors.forename: E L
authors.initials: EL
authors.lastname: Madsen
authors.forename: C
authors.initials: C
authors.lastname: Fenger
authors.forename: M R
authors.initials: MR
authors.lastname: Poulsen
authors.forename: O F
authors.initials: OF
authors.lastname: Petersen
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery; D003110:Colonic Neoplasms / Q000601:surgery; D005234:Fatty Liver / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012004:Rectal Neoplasms / Q000601:surgery; D014057:Tomography, X-Ray Computed
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002955:Leucovorin; D005472:Fluorouracil